Cover Image
市場調查報告書

蛋白酪氨酸激酶抑制劑的市場及開發平台分析 (2015年)

Tyrosine Kinase Inhibitors Market & Pipeline Insight 2015

出版商 KuicK Research 商品編碼 327760
出版日期 內容資訊 英文 1200 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
蛋白酪氨酸激酶抑制劑的市場及開發平台分析 (2015年) Tyrosine Kinase Inhibitors Market & Pipeline Insight 2015
出版日期: 2015年04月03日 內容資訊: 英文 1200 Pages
簡介

近年來,全球各國蛋白酪氨酸激酶治療藥的開發正在急速發展。在研究開發 (R&D) 活動投入巨額資金的結果,讓許多產品陸續開始開發,今後數年間預測將達到臨床實驗的各個階段。由於部分產品含有單株抗體(mAB),產品化的成本增加,但由於患者群巨大及藥理上的優勢,可望對今後市場成長帶來莫大貢獻。今後數年由於陸續有創新醫藥品的藥物研發、實驗、上市,預測將有更多的高成本效率之治療選擇出現。由於市場急速擴大,預計蛋白酪氨酸激酶治療藥可治療的疾病數也將會日益增加。

本報告提供全球的蛋白酪氨酸激酶抑制劑市場趨勢,及開發平台產品的開發情形相關分析,提供蛋白酪氨酸激酶抑制劑 (治療藥) 的特性和作用機制,整體市場結構·趨勢,開發中產品的目前開發情形,產品單位 (計239產品) 的詳細開發情形,已上市產品 (計53產品) 銷售情形,今後的市場方向性等資訊,為您概述為以下內容。

第1章 蛋白酪氨酸激酶抑制劑的概要

第2章 蛋白酪氨酸激酶治療藥的機制

第3章 全球蛋白酪氨酸激酶治療藥市場概要

  • 目前市場方案
  • 蛋白酪氨酸激酶抑制劑的臨床實驗平台概況

第4章 全球蛋白酪氨酸激酶治療藥市場動態

  • 良好的市場指標
  • 市場課題

第5章 全球蛋白酪氨酸激酶治療藥市場未來展望

第6章 全球蛋白酪氨酸激酶抑制劑的開發平台:各企業·各適應症·各相 (階段)

  • 不明
  • 研究階段
  • 前臨床階段
  • 臨床階段
  • 第一階段
  • 第一/二階段
  • 第二階段
  • 第二/三階段
  • 第三階段
  • 認證前
  • 已認證

第7章 已上市的蛋白酪氨酸激酶抑制劑:各企業·各適應症

第8章 臨床實驗延期·中斷的蛋白酪氨酸激酶抑制劑的開發中產品

  • 沒有開發資訊的
  • 臨床實驗中止的
  • 市場撤退
  • 臨床實驗延期

第9章 競爭環境

  • Advenchen Laboratories
  • Array Pharmaceuticals
  • AstraZeneca
  • Bayer Healthcare Pharmaceuticals
  • Biogen Idec
  • Bristol-Myer Squibb
  • Boehringer Ingelheim
  • 中外製藥
  • Celgene Corporation
  • Exelixis
  • Incyte Corporation
  • GalaxoSmithKline
  • Johnson & Johnson
  • Merck
  • Novartis
  • Onyx pharmaceuticals
  • Pfizer
  • Sanofi
  • Tolero Pharmaceutical
  • QIAGEN

圖表一覽

目錄

Tyrosine kinase is a sub class of Protein Kinases family of enzyme responsible for phosphorylation.It has been found that mutation or other anomaly in these enzymes causes uncontrolled cell division leading to cancer. Because of their direct involvement in cell division they are used in cancer treatment by using kinase inhibitors to prevent unregulated cellular proliferation. Epidermal Growth Factor Receptor Family (EFGR) are present on the cell surface and anomalies like mutations leads to the cancer formation and its members have been found to have activity like receptor tyrosine kinases. EFGR Members of these families have been found to be overexpressed in various malignancies like breast cancer, glioblastoma and lung cancer. They are utilized for formulating targeted therapeutics for cancer treatment. Her1/ Her2 are commonly found to be overexpressed in case of breast cancer and many cancer therapeutics have been developed to treat metastatic condition.

Tyrosine kinase therapeutics segment is rapidly growing along with numerous products at various phases of industry life cycle. Huge investments in research and development segment could be attributed as main reason behind growth of this market segment. As a result, several products are at different stages of clinical trials which will be introduced in market in coming years. Some tyrosine kinase medical care products including mAbs are costly to produce but large patient base and superior pharmacological benefits are some factors responsible for continuous growth of this market segment. Development and discovery of innovative technologies for commercialization is increasing because of large financial inputs. As a result, more therapeutic options will be available to patients at cost effective rates. Their disease coverage is increasing continuously due to which their market penetration is expected to increase several folds in coming years.

Increasing disease incidences especially cancer has attracted several pharmaceutical companies to invest in this segment. Imatinib (protein-tyrosine kinase inhibitor) for CML treatment by Novartis was the first of this kind to enter in global market. Targeted therapeutics offer superior pharmacological benefits due to which profit margin of tyrosine kinase inhibitors are expected to increase in coming years. Small molecule based targeted therapeutics will offer competition to monoclonal antibodies in terms of pharmacological efficacy but pricing and commercialization strategies are also expected to play a major role.

Monoclonal antibodies are widely accepted across the globe due to higher safety and efficacy profiles along with minimized side effects. Several mAbs biding to different tyrosine receptors have been formulated by pharmaceutical companies generating significant revenues across the globe. For instance, Genentech's trastuzumab binds to HER2 for breast cancer treatment while Bevacizumab binds to VEGF to treat NSCLC. Pharmaceutical companies are developing cancer drugs to target same receptor kinase due to which severe competition would be found in certain categories. EFGR is widely studied due to which majority of tyrosine kinase therapeutics belong to this category. Moreover, it is involved in breast cancer which has well developed market so revenues generated by this segment are expected to be significantly higher than other cancer categories.

Clinical pipeline of tyrosine kinase therapeutics is quite strong due to which competitive product are expected to enter continuously in global market. Owing to increasing disease incidences, it has become imperative to take necessary steps to introduce innovative tyrosine kinase therapeutics in global market. Technological advancements may allow the investigators to develop products having high safety and efficacy levels along with minimized side effects but it will take some time. Various products are at different stages of clinical trials which will be introduced in global market in coming years. Higher cost effectiveness is expected due to which sales is expected to increase and profit margins will increase. With all these development, the future of tyrosine kinase therapeutics looks optimistic.

" Tyrosine Kinase Inhibitors Market & Pipeline Insight 2015" Report Highlight:

  • Global Tyrosine Kinase Therapeutics Market Overview
  • Mechanism of Tyrosine Kinase Therapeutics
  • Global Tyrosine Kinase Inhibitors Pipeline by Company, Indication & Phase
  • Global Tyrosine Kinase Inhibitors Pipeline: 557 Drugs
  • Majority Drugs in Preclinical Phase: 239 Drugs
  • Marketed Tyrosine Kinase Inhibitors: 58 Drugs
  • Marketed Tyrosine Kinase Inhibitors Clinical Analysis by Company & Indication

Table of Contents

1. Introduction to Tyrosine Kinases Inhibitors

2. Mechanism of Tyrosine Kinase Therapeutics

3. Global Tyrosine Kinase Therapeutics Market Overview

  • 3.1 Current Market Scenario
  • 3.2 Tyrosine Kinase Inhibitors Pipeline Overview

4. Global Tyrosine Kinase Therapeutics Market Dynamics

  • 4.1 Favorable Market Parameters
  • 4.2 Market Challenges

5. Global Tyrosine Kinase Therapeutics Market Future Prospects

6. Global Tyrosine Kinase Inhibitors Pipeline by Company, Indication & Phase

  • 6.1 Unknown
  • 6.2 Research
  • 6.3 Preclinical
  • 6.4 Clinical
  • 6.5 Phase-I
  • 6.6 Phase-I/II
  • 6.7 Phase-II
  • 6.8 Phase-II/III
  • 6.9 Phase-III
  • 6.10 Preregistration
  • 6.11 Registered

7. Marketed Tyrosine Kinase Inhibitors by Company & Indication

8. Suspended & No Development Reported Tyrosine Kinase Inhibitors Pipeline

  • 8.1 No Development Reported
  • 8.2 Discontinued
  • 8.3 Market Withdrawal
  • 8.4 Suspended

9. Competitive Landscape

  • 9.1 Advenchen Laboratories
  • 9.2 Array Pharmaceuticals
  • 9.3 AstraZeneca
  • 9.4 Bayer Healthcare Pharmaceuticals
  • 9.5 Biogen Idec
  • 9.6 Bristol-Myer Squibb
  • 9.7 Boehringer Ingelheim
  • 9.8 Chugai Pharmaceutical
  • 9.9 Celgene Corporation
  • 9.10 Exelixis
  • 9.11 Incyte Corporation
  • 9.12 GalaxoSmithKline
  • 9.13 Johnson & Johnson
  • 9.14 Merck
  • 9.15 Novartis
  • 9.16 Onyx pharmaceuticals
  • 9.17 Pfizer
  • 9.18 Sanofi
  • 9.19 Tolero Pharmaceutical
  • 9.20 QIAGEN

List of Figures and Tables

  • Figure 1-1: Flow Chart of Phosphorylation
  • Figure 1-2: Hierarchy of EFGR Family
  • Figure 1-3: Hierarchy of VEGFR Family
  • Figure 1-4: Features of Receptor Tyrosine Kinase
  • Figure 1-5: Benefits of Tyrosine Kinase Inhibitors
  • Figure 2-1: Properties of Tyrosine Kinase Therapeutics
  • Figure 2-2: Mechanism of Nexavar
  • Figure 2-3: Mechanism of Gleevac
  • Figure 2-4: Mechanism of Tyverb
  • Figure 2-5: Benefits of Monoclonal Antibodies
  • Figure 2-6: Mechanism of Avastin
  • Figure 2-7: Mechanism of Rituximab
  • Figure 3-1: Tyrosine Kinase Inhibitors Pipeline by Phase (%), 2015
  • Figure 3-2: Tyrosine Kinase Inhibitors Pipeline by Phase (Numbers), 2015
  • Figure 3-3: No Development Reported in Tyrosine Kinase Inhibitors Pipeline by Phase (%), 2015
  • Figure 3-4: No Development Reported in Tyrosine Kinase Inhibitors Pipeline by Phase (Number), 2015
  • Figure 3-5: Discontinued Tyrosine Kinase Inhibitors Pipeline by Phase (%), 2015
  • Figure 3-6: Discontinued Tyrosine Kinase Inhibitors Pipeline by Phase (Number), 2015
  • Figure 3-7: Suspended Tyrosine Kinase Inhibitors Pipeline by Phase (%), 2015
  • Figure 3-8: Suspended Tyrosine Kinase Inhibitors Pipeline by Phase (Number), 2015
  • Figure 4-1: Tyrosine Kinase Therapeutics Favorable Market Parameters
Back to Top